BioLife Solutions (BLFS) Projected to Announce Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS – Get Free Report) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $29.13 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

BioLife Solutions (NASDAQ:BLFS – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.88. The company had revenue of $28.47 million for the quarter, compared to analyst estimates of $27.80 million. BioLife Solutions had a return on equity of 2.70% and a net margin of 53.29%. On average, analysts expect BioLife Solutions to post $0.03 EPS for the current fiscal year and $0.16 EPS for the next fiscal year.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock opened at $38.61 on Thursday. The company has a market capitalization of $1.89 billion, a PE ratio of 33.28 and a beta of 1.82. The company has a 50-day simple moving average of $37.46 and a two-hundred day simple moving average of $27.81. BioLife Solutions has a one year low of $17.86 and a one year high of $39.76.

Analyst Ratings Changes

A number of analysts have recently weighed in on BLFS shares. Zacks Research cut shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, September 21st. Lake Street Capital downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating and cut their price objective for the stock from $33.00 to $31.00 in a research report on Wednesday, July 22nd. Jefferies Financial Group lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $30.00 to $31.00 in a research note on Thursday, July 23rd. Benchmark cut shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Monday, August 10th. Finally, Maxim Group cut shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $31.38.

Read Our Latest Stock Report on BLFS

About BioLife Solutions

(Get Free Report)

BioLife Solutions, Inc develops and supplies products and services used to preserve, process, store and transport biological materials. Its solutions support the development and manufacture of cell and gene therapies, including products designed to help maintain the viability and functionality of cells, tissues and other biologic materials throughout the bioprocessing workflow.

The company’s portfolio includes preservation media such as CryoStor and HypoThermosol, cell thawing and handling products, and related storage and shipping systems.

Further Reading

Earnings History for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.